pcn poster

Posters

Impact of Clinician and Practice Characteristics on Utilization of and Attitudes Toward Long-Acting Injectable Antipsychotics in Schizophrenia: A Survey of US-Practicing Psychiatric Clinicians (DECIDE)

Abstract: Background: Social determinants of health (eg, race/ethnicity, resources) impact quality of care for a number of chronic diseases. Methods: In DECIDE, US-based psychiatric clin...

08/20/2024

Sustained Response to Esketamine Nasal Spray in Patients With Treatment-Resistant Depression: Analysis of Long-Term Data from the SUSTAIN-2 Study

Abstract: Background: This post hoc analysis of SUSTAIN-2 (NCT02497287), an open-label, long-term safety and efficacy study of esketamine nasal spray (ESK), assessed sustained response (S...

08/20/2024

Long-term Safety, Tolerability, and Effectiveness of TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA)—in Patients With Schizophrenia: A Phase 3, Randomized, Double-Blind Study (SHINE)

Abstract: Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative, copolymer-based drug delivery technology. In the RISE study...

08/20/2024

The Efficacy and Safety of Esketamine Nasal Spray Versus Quetiapine Extended Release Over 32 Weeks in Patients With Treatment-Resistant Depression: A Subgroup Analysis of the ESCAPE-TRD Study

Abstract: Objective: ESCAPE‑TRD (NCT04338321), a randomized, open-label, rater-blinded, trial demonstrated benefits for esketamine nasal spray (ESK) versus quetiapine extended release (QX...

08/20/2024

Matching-adjusted Indirect Treatment Comparison and Network Meta-Analysis of Zuranolone to Standard-of-care Antidepressant Therapies for the Acute Treatment of Adults with Major Depressive Disorder

Abstract: Background: Major depressive disorder (MDD) is a debilitating disease for which there is an unmet need for rapid-acting treatments. Zuranolone is an investigational oral, once-d...

08/20/2024

The SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Safety and Efficacy of TV-44749 (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsycho...

08/20/2024

Medication Adherence and Healthcare Resource Utilization in South Carolina Medicaid Beneficiaries with Schizophrenia or Schizoaffective Disorder: Long-acting Injectable vs. Oral Antipsychotics

Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utiliz...

08/20/2024

Total Cost of Care Following First-Line Antidepressant Treatment Failure Among Patients With Major Depressive Disorder in the United States

Abstract: OBJECTIVES: To evaluate total all-cause healthcare costs among US patients diagnosed with major depressive disorder (MDD) who failed first-line antidepressant treatment (ADT). ...

08/20/2024

Patient Outcomes Post Hospitalization Discharge Among Patients With Schizophrenia Treated With a Long Acting Injectable or Switched to a New Oral Antipsychotic Medication

Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health ca...

08/20/2024

Transitioning Patients to Long-Acting Injectable Antipsychotics: Attitudes and Perceptions of US Clinicians Based on a Hypothetical Case (Results from the DECIDE Survey)

Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to ...

08/20/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products